At a time when recent clinical outcomes have highlighted the limits of GLP-1–based strategies in Alzheimer’s disease https://lnkd.in/drNryJvQ, the need for targeted, mechanism-driven interventions has never been clearer. The setback in #GLP-1 #Alzheimer’s trials reinforces a simple point: metabolic improvement alone is not enough to halt early neurodegenerative processes.
Proud of this milestone and of the vision shared with Giuseppe Daniele.
Onward to building the next generation of metabolic–neuroinflammatory therapeutics.
- Notizia: https://www.unipi.it/index.php/news/item/20913-dall-ateneo-un-innovativo-brevetto-per-la-cura-di-diabete-obesita-e-malattie-neurodegenerative
